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Supporting Information  24  25  26  27  28  29  30  31  32  33  34  35  36 S ABSTRACT: Multidrug resistant bacteria have emerged as a threat to public health all 37 over the world. At the same time, the discovery of new bioactive small molecules with 38 antimicrobial activity and suitable pharmacological properties has waned. Herein we 39 report the screening of marine extracts to identify novel compounds with antimicrobial 40 activity. Bioassay guided fractionation has enabled the discovery and identification of a 41 family of simple amines with promising activity against methicillin resistant 42
Staphylococcus aureus (MRSA). To confirm the natural product structures proposed, 43 these compounds and analogues have been prepared synthetically. Several of the 44 synthetic analogues showed promising bioactivity against the medically important 45 pathogens MRSA (MICs to 12.5 µM), Mycobacterium tuberculosis (MICs to 0.02 µM), 46
uropathogenic Escherichia coli (MIC 6.2 µM) and Pseudomonas aeruginosa (MIC 3.1 47 µM). Cross-referencing antimicrobial activity and toxicity show that these synthetic 48 compounds display a favourable therapeutic index for their target pathogens. 49 50 51 52 53 54 55 1. INTRODUCTION 56 Marine ecosystems have long been a rich source of bioactive natural products, in the 57 search for interesting molecules and novel therapeutic agents. [1] [2] [3] [4] [5] Many interesting and 58 structurally diverse secondary metabolites have been isolated from marine sources and 59 characterised over the last 70 years. [6] [7] [8] [9] Yet the first 'drugs from the sea' were only 60 approved in the early 2000s: the cone snail peptide ziconotide (ω-conotoxin MVIIA) in 61 2004 to alleviate chronic pain, 10 and sea squirt metabolite trabectedin in 2007 for 62 treatment of soft-tissue sarcoma. 11 Interest in marine natural products has continued to 63 grow since, 6, [8] [9] spurred in part by the spread of antimicrobial resistant pathogens and the 64 need for new drugs to combat them. 3 65 66 Human pathogens are associated with a variety of moderate to severe infections and the 67 recent rise of multi-drug resistant pathogens makes treatment more difficult. The last 68 two decades have seen the emergence of methicillin resistant Staphylococcus aureus 69 (MRSA) strains resistant even to 'drugs of last resort' such as vancomycin, 12 and 70
Mycobacterium tuberculosis resistant to all front-line drugs, [13] [14] [15] which highlights the 71 urgent need to find new effective antibiotics. Natural products continue to offer a 72 productive source of structural diversity and bioactivity, and are an important source for 73 new drugs. 3-4, 6-7 74 75 In the search for new antimicrobial agents, we screened a set of marine extracts 16 to 76 determine activity against antibiotic resistant microorganisms using a high-throughput 77 screening (HTS) assay. Fractionation and purification of active components by high-78 performance liquid chromatography (HPLC) and structural elucidation using high 79 resolution and tandem mass spectrometry (MS) led us to a series of potential structures 80 for new, bioactive amine natural products ( Figure 1 ). 81
82
To validate the proposed structures, and to explore the potential of this compound class 83 more broadly, analogues based on the general structures 1-5 were synthesised and 84 were screened in a resazurin cell viability assay. Of the samples tested, 29 inhibited the 97 growth of MRSA by greater than 50% compared to non-treated controls ( Figure S1 , 98 Supporting Information). Minimum inhibitory concentrations (MICs) were determined 99 for the 23 most promising samples, representing extracts and fractions from the phyla 100 Porifera (90%), Echinodermata (5%) and Chordata (5% (Table 1 and Table S1 ). explore the potential of these a compounds as bioactive agents, a series of tertiary amine 154 derivatives of compounds 1-5 were synthesised from 1-bromooctane 6, m-toluidine 7, 155 p-toluidine 8, benzyl amine 9, 1-iododecane 10, N, N-dihexylamine 11 and N,N,N-156 trioctylamine 12 (Schemes 1 and 2). o-Toluidine is carcinogenic and therefore was not 157 used in synthetic experiments. While the yields of many synthetic steps were low, sufficient quantities of material were 188 nonetheless isolated to enable characterisation, and biological evaluation, so the 189 synthetic reactions were not further optimised. 190
Structural Comparison of Synthetic Compounds to Natural Products. 191
Synthetic compounds were investigated using mass spectrometry (MS/MS and accurate 192 mass) and analysis of biological activity. Comparing the major ions in the mass spectra 193 of synthetic 1a and 1b (Table S8) , 2a (Table S9) , 3 (Table S10 ) and 13 ( Figure S11 ) 194 with the natural products shows good correlation (Tables S6, S5 and S7, and Figures S9 , 195 S11 and S13 respectively). Some minor differences are apparent, which most likely arise 196 due to differences in the amounts of material analysed (which are significantly greater 197 for the synthesized products), and differences in the instrumentation used. The potential toxicity of the synthetic compounds was also evaluated, against A549, 219 THP-1, HepG2 and HEK 293 and cell lines ( Table 3) . None of the synthetic compounds 220 showed significant toxicity against HepG2 or A549 cells. Synthetic compounds 1a, 2a, 221 3, 13 and 18 all showed some toxicity against THP1 and/or HEK 293 cells, with 222
Minimum Toxicity Concentrations (MTC) as low as 3.1 µM. Compound 1b showed low 223 toxicity against all four of these cell lines, but also low activity ( 
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Comparing data from the antimicrobial activity and cytotoxicity assays shows that the 236 active concentration ranges for these synthetic compounds against bacteria are 237 substantially lower than active concentration ranges against the mammalian cells tested, 238 particularly HepG2 and A549 cells. THP1 cells and the primary cells appeared more 239 sensitive to these compounds. Cross-referencing the biological activity and toxicity data 240 for these compounds suggest that they have some potential for further development. 241
Compounds 1a, 13 and 18, which showed the most promising activity against M. 242 tuberculosis, were assessed against single and multi-drug resistant M. tuberculosis 243 strains (Table 5 ). Compound 13 exhibited strong inhibitory activity against all resistant 244 strains with MICs as low as 0.24 µm; Compound 1a showed moderate and variable 245 activity against all assay strains (MIC 6.7-20.0 µm) and 18 showed similar activity 246 against all resistant strains with an MIC of 2.2 µm. 247 248 
Screening the AIMS Extract Library Against MRSA. Each test sample (10 µL) 296
was dispensed into a separate well of a 96 well microtiter plates (final sample 297 concentration 0.5 mg mL −1 ) using sterile dH 2 O. Bacterial suspension (90 µL, OD 600nm 298 0.001) was added to each well and plates were incubated at 37 o C for 18 hours. To 299 determine MIC of samples, crude extracts were added to wells in sequential 2-fold 300 dilutions and incubated with diluted bacteria as described previously. [23] [24] Resazurin ( Eagle's medium) tissue culture media (RPMIc and DMEMc). To determine toxicity of 312 the AIMS extract library, 2 × 10 5 of each cell type were added to a 96-well plate and left 313 for 48 h at 37 °C to adhere. Extract samples at a final concentration of 0.5 mg mL -1 were 314 added to the wells, then incubated for 7 days in a humidified 5% CO 2 incubator at 37 315 °C. Then resazurin (10 μ L of 0.05% w/v) was added and after 4 h, fluorescence 316 measured as described previously. Cell viability was calculated as percentage 317 fluorescence relative to untreated cells. 318 injected onto an analytical Waters X-bridge C18 100 A (4.6 × 250 mm, 5 µm) reversed-328 phase column on the same analytical HPLC system described above. The mobile phase 329 was obtained using 100% acetonitrile and 0% water at a flow rate of 1 ml min -1 at 30 ºC 330 over 80 min. Fractions, separated every 60 s, were collected. Purified fractions were 331 flash-frozen in liquid nitrogen then freeze-dried overnight. The resulting fractionated 332 extracts were re-suspended in DMSO and antibacterial activity versus MRSA was 333 determined as described above. 334 335 Fractions identified as active against MRSA were further purified on the preparative 336 HPLC unit described above, using a C18 100 A (250 × 21.2 mm, 10 µm) reversed-337 phase column (Phenomenex) with UV detection at 254 and 280 nm, 7 mL min -1 flow 338 rate with water/acetonitrile gradient containing 0.1% trifluoroacetic acid. 339
340
The gradient for AIMS extracts 19033, 20608, and 26051 was 0% B initially, increased 341 to 40% B over 20 min, then to 100% at 60 min, held at 100% for 10 min, and finally a 342 linear decrease to 0% B over 5 min and held at 0% B for 10 min prior to the next run. 343
Compounds thus purified were evaluated for biological activity and analysed by MS to 344 determine potential structures for the bioactive components. 1. N,N-Dioctyl-3-methylaniline 1a. To a solution of 1-bromooctane 6 (6.3 mL, 36.6 368 mmol) in acetonitrile (50 mL) was added potassium carbonate (25.3 g, 183 mmol), KI 369 (6.08 g, 36.6 mmol) and m-toluidine 7 (1.96 mL, 18.3mmol) stirred at 60 °C overnight. 370
The suspension was filtered and washed with acetonitrile (3 × 50 mL), then 371 concentrated by rotary evaporation to yield the crude product (1.50 g). Purification by 372 automated column chromatography (100 g cartridge, 100% petroleum benzine over 12 7, 129.0, 116.0, 112.4, 109.0, 51.0, 31.8, 29.5, 29.3, 27.3, 27.2, 22.7, 22.0, 14. 390 129.7, 124.3, 112.2, 51.3, 31.9, 29.5, 29.4, 27.3, 27.2, 22.7, 20.1, 14. 5.3. N-Benzyl-N-octyloctan-1-amine 2a . To a solution of 1-bromooctane 6 (6.3 mL, 395 36.6 mmol) in acetonitrile (50 mL) were added potassium carbonate (25.3 g, 183 mmol) 396 and benzylamine 9 (2 mL, 18 mmol) then stirred at 60 ºC overnight. The mixture, a clear 397 colourless solution, was concentrated using the rotary evaporator, to give a white solid. 398
The solid was triturated with DCM (1 × 50 mL, 1 × 25 mL) and the DCM solution 399 concentrated on the rotary evaporator to yield yellow oil ( 3, 128.8, 128.0, 405 126.6, 58.6, 53.8, 31.9, 29.6, 29.3, 27.5, 27.0, 22.7, 14. 4. N,N-Dihexyldecan-1-amine 3. To a solution of 1-iododecane 10 (2.75 mL, 12.9 410 mmol) in acetonitrile (60 mL) was added potassium carbonate (16.5 g, 129 mmol) and 411 dihexylamine 11 (3 mL, 12.9 mmol), then the mixture was stirred at reflux overnight. 412
The suspension was filtered to remove K 2 CO 3 and washed with acetonitrile (3 × 50 mL), 413 then concentrated by rotary evaporation to yield the crude product (7.8 g). The crude 414 product was purified by automated column chromatography (100 g cartridge, 100% 415 petroleum benzene 2CV, then 0-60% ethyl acetate in petroleum benzene over 10 CV) to 416 yield the product as an oil (0.89 g, 21 % 54.2, 31.9, 31.9, 29.7, 29.6, 29.6, 29.3, 27.7, 27.4, 26.9, 419 22.7, 14.1, 14. 5. N,N,N-Trioctylammonium chloride 13 . To a solution of N,N,N-trioctylamine 12 422
(1.0 g, 2.80 mmol) in 1,4-dioxane (1.0 mL) was added 4M HCl in dioxane (2.80 mL, 423 11.2 mmol) in an ice bath. Instantaneously a precipitate formed and after 5 min this was 424 collected by vacuum filtration to yield a white solid (1.08 g, 99 % yield 427 31.4, 28.8, 28.7, 26.6, 23.0, 22.3, 13.8. 428 429 4.5. 6. N-(But-3-yn-1-yl)-N-octyloctan-1-amine 83.3, 68.7, 54.0, 52.7, 31.8, 29.6, 29.3, 27.6, 27.2, 22.6, 440 16.7, 14. (3 x 50 mL), then the filtrate was concentrated by rotary evaporation and purified by 450 automated column chromotography (100g cartridge, 0%-20% methanol in 451 dichloromethane over 8 CV). Purified fractions were re-purified by automated reversed 452 phase chromotography (30g cartridge C18 silica (Biotage), 0%-90% acetonitrile in 453 water over 17 CV) and concentrated to yield the product as a yellow solid (10 mg, 1%). δ 162.4, 161.9, 458 142.1, 136.8, 131.2, 129.6, 128.1 (128.09), 128.1 (128.08), 127.7, 125.4, 124.1, 123.2, 459 122.6, 122.1, 51.6, 51.3, 34.8, 30.6, 28.7, 28.0, 25.7, 22.0, 21.5, 20.1, 13.0, 12.3 
